This is a phase II SBIR Contract to develop broad spectrum monoclonal antibodies against enteroviruses. Enteroviruses cause neurological diseases mainly in young children including acute flaccid myelitis (AFM) and Hand Foot and Mouth Disease (HFMD). There is no therapeutics against these viruses or vaccines against them approved in the US. These viruses are members of picornavirus family, a priority pathogen of NIAID because of their high pandemic potential.